Similarly, a humanized anti-CD30 antibody (XmAb2513; Xencor) with enhanced binding to FcγRIIIa is being evaluated in the treatment of CD30+ Hodgkin’s lymphoma (HL) patients who had previously received two or more therapies (89, 92, 93). This evidence concerns the gene TNFRSF8 and Hodgkins lymphoma.